Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.
Cancer Cell
; 41(5): 821-823, 2023 05 08.
Article
in En
| MEDLINE
| ID: mdl-37116490
ABSTRACT
Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hematologic Neoplasms
/
COVID-19
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Cancer Cell
Journal subject:
NEOPLASIAS
Year:
2023
Document type:
Article
Affiliation country: